Protocols Report
180 Active protocols found listed by cooperative groupReport Date: 7/31/2015 5:24:26 PM
ALLIANCE
Protocol IDPhaseLead OrganizationProtocol Title
A011203
Breast Cancer
IIALLIANCE
A031102
Miscellaneous Neoplasm
IIIALLIANCE
CALGB-10701
Leukemia
IIALLIANCEA Phase II Study of Dasatinib (Sprycel) (IND #73969, NSC #732517) as Primary Therapy followed by Transplantation for Adults ≥ 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
CALGB-140503
Lung Cancer
IIIALLIANCEA Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<=2 cm) Peripheral Non-Small Cell Lung Cancer
CALGB-30610
Lung Cancer
IIIALLIANCEPhase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
CALGB-30901
Lung Cancer
IIALLIANCERandomized phase II study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first-line chemotherapy
CALGB-51101
Lymphoma
IIALLIANCEA Randomized Phase II Trial of Myeloablative versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
CALGB-70807
Genitourinary Cancer
IIIALLIANCEThe Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
CALGB-80702
Gastrointestinal Cancer
IIIALLIANCEA phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancer
CALGB-80802
Gastrointestinal Cancer
IIIALLIANCE
CALGB-80803
Gastrointestinal Cancer
IIALLIANCERandomized Phase II Trial Of Pet Scan-Directed Combined Modality Therapy In Esophageal Cancer
CALGB-90203
Genitourinary Cancer
IIIALLIANCEA Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
CALGB-90601
Genitourinary Cancer
IIIALLIANCE A Randomized doubled-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab to gemcitabine, cisplatin, and placebo in patients with advanced transitional cell carcinoma
N0577
CNS Primary
IIIALLIANCEPhase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
N1048
Gastrointestinal Cancer
II/IIIALLIANCEA Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
N107C
CNS Metastases (see Metastatic Cancer)
IIIALLIANCEA Phase III Trial of Post-Surgical Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
A011104
Breast Cancer
IIIALLIANCEEffect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
A011106
Breast Cancer
IIIALLIANCEAlternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
A011202
Breast Cancer
IIIALLIANCEA Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A021101
Gastrointestinal Cancer
PilotALLIANCE***Temporary Suspension of this Study Effective February 4, 2014***
Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients with Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study
A021202
Carcinoid
IIALLIANCEProspective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors
A031201
Genitourinary Cancer
IIIALLIANCEA Phase III Trial of Enzalutamide (NSC#766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
A031203
Genitourinary Cancer
IIALLIANCE*** Alliance Only Study***
Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma
A041202
Leukemia
IIIALLIANCEA Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
A051103
Lymphoma
IALLIANCE***Limited Access Study, Available Only to the Institutions Specified on the Protocol Cover Page***
A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular lymphoma
A051201
Lymphoma
I/IIALLIANCE*** Alliance Study: Phase I Select Site Participation - Phase II Available to Alliance Sites Only***
A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma
A051202
Lymphoma
IALLIANCE***Limited Access Study, Available Only to the Institutions Specified on the Protocol Cover Page***
A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
A061202
Myeloma
I/IIALLIANCE*** Alliance Only Study***
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
A071101
CNS Primary
IIALLIANCEA Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND# 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resective Recurrent Glioblastoma Multiforme (GBM)
A081105
Lung Cancer
IIIALLIANCERandomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
A091101
Head and Neck Cancer
I/IIALLIANCE*** New Patient Accrual Suspended Immediately - Effective, May 29, 2013***
*** Alliance Only Study***
TPF Induction Chemotherapy and Veliparib: A Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
A091102
Sarcoma
IIALLIANCE*** Alliance Only Study***
A Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
A091105
Sarcoma
IIIALLIANCEA Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
A091201
Melanoma
IIALLIANCE*** Alliance Only Study***
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
A091202
Miscellaneous Neoplasm
IIALLIANCEA Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma
A091305
Head and Neck Cancer
IIALLIANCEA Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, In Combination with Paclitaxel Versus Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer
A211102
Breast Cancer
IIIALLIANCETesting for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology after 12 months Metformin (1,1-dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control
A211201
Breast Cancer
IIALLIANCEChange in Mammographic Density with Metformin Use: A Companion Study to NCIC Study MA.32
A221101
Brain Cancer
IIIALLIANCEA Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma
A221102
Breast Cancer
IIIALLIANCERandomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias
A221301
Miscellaneous Neoplasm
IIIALLIANCE***Alliance Sites Only***
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)
CALGB-31102
Lung Cancer
IALLIANCE***Cohort 4 was opened to accrual effective December 4, 2013***
***Study Temporarily Suspended Effective October 17, 2013***
***Limited Participation Study***
Phase I Study of Accelerated Hypofractionated Radiation Therapy with Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
CALGB-40903
Breast Cancer
IIALLIANCE*** Alliance Only Study***
Phase II Study Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in SITU (DCIS)
CALGB-50801
Lymphoma
IIALLIANCE*** Alliance Only Study***
A Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
CALGB-50904
Lymphoma
IIALLIANCE*** Alliance Only Study***
A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib and Bendamustine in Patients with Untreated Follicular Lymphoma
CALGB-9665
Non-Therapeutic
OtherALLIANCE*** Alliance Only Study***
The Alliance Hematologic Malignancy Biorepository
GLNE010
Gastrointestinal Cancer
IIALLIANCE*** STUDY NO LONGER OPEN TO NEW SITE PARTICIPATION EFFECTIVE AUGUST 10, 2012***
Validation and comparison of biomarkers for the early detection of colorectal adenocarcinoma
N1174
CNS Primary
I/IIALLIANCEPhase 1/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme
Z11102
Breast Cancer
OtherALLIANCEThis study is open to participation by all CTSU member sites.
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
CITN
Protocol IDPhaseLead OrganizationProtocol Title
CITN-04
Melanoma
IICITNA Phase II Pilot Trial of an Indoleamine2,3, dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients with Advanced Melanoma
CITN-05
Gynecologic Cancer
PilotCITNA Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
CITN-06-ALT-803
Melanoma
ICITNA Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Melanoma
CITN-07-FLT3L
Melanoma
IICITNA Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand
CITN-09
Miscellaneous Neoplasm
IICITNA Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC)
CITN-10
Lymphoma
IICITNA Phase II Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides / Sézary Syndrome
CITN11-02
Melanoma
ICITNA Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer
CITN12-03
Genitourinary Cancer
IICITN
COG
Protocol IDPhaseLead OrganizationProtocol Title
AEWS1031
Sarcoma
IIICOGA Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
AEWS1221
Sarcoma
IICOG
AOST1322
Sarcoma
IICOG
ECOG-ACRIN
Protocol IDPhaseLead OrganizationProtocol Title
ACRIN-6701
Genitourinary Cancer
OtherECOG-ACRIN
E1208
Gastrointestinal Cancer
IIIECOG-ACRINA Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion
E1305
Head and Neck Cancer
IIIECOG-ACRINA Phase III Randomized Trial of Cisplatin and Docetaxel with or without Bevacizumab In Patients with Recurrent or Metastatic Head and Neck Cancer
E1311
Head and Neck Cancer
IIECOG-ACRINA randomized phase II trial of Afatinib (BIBW2992) as adjuvant therapy following chemoradiation in patients with head and neck squamous cell carcinoma at high risk of recurrence
E1411
Lymphoma
IIECOG-ACRINIntergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
E1412
Lymphoma
IIECOG-ACRINRandomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
E1512
Lung Cancer
IIECOG-ACRINA Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC
E1609
Melanoma
IIIECOG-ACRINE1609 is re-opened to pediatric accrual effective September 23, 2014. Adult accrual will remain closed.
E1808
Genitourinary Cancer
IIECOG-ACRIN
E1910
Leukemia
IIIECOG-ACRINA Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
E1912
Leukemia
IIIECOG-ACRINA Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
E1A11
Myeloma
IIIECOG-ACRINRandomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma
E1Q11
Miscellaneous Neoplasm
OtherECOG-ACRINEROS: Engendering Reproductive Health within Oncologic Survivorship
E1Z11
Breast Cancer
OtherECOG-ACRIN***THE CAUCASIAN/OTHER RACES COHORT FOR E1Z11 WILL BE CLOSED TO ACCRUAL EFFECTIVE FEBRUARY 24, 2014 ***
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E2108
Breast Cancer
IIIECOG-ACRINA Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer
E2112
Breast Cancer
IIIECOG-ACRINA Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
E2211
Gastrointestinal Cancer
IIECOG-ACRINA Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumor
E2212
Gastrointestinal Cancer
IIECOG-ACRINA Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver
E2511
Lung Cancer
I/IIECOG-ACRINPhase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
E2607
Melanoma
IIECOG-ACRINA Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas
E2810
Genitourinary Cancer
IIIECOG-ACRINRandomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Subjects with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy
E2905
Leukemia
IIIECOG-ACRINRandomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
E2906
Leukemia
IIIECOG-ACRINPhase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytosine Arabinoside Induction and Intermediate Dose Cytosine Arabinoside Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age Greater Than or Equal to 60 Years).
E3108
Breast Cancer
IIECOG-ACRIN***STUDY WILL TEMPORARILY CLOSE TO ACCRUAL EFFECTIVE June 21, 2013 at 5:00 PM Eastern Time***
A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen
E3311
Head and Neck Cancer
IIECOG-ACRINPhase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
E3903
Leukemia
OtherECOG-ACRIN
E3A06
Myeloma
IIIECOG-ACRINRandomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic Smoldering Multiple Myeloma
E3F05
CNS Primary
IIIECOG-ACRIN***NEW ACCRUAL TO THIS STUDY IS SUSPENDED EFFECTIVE FEBRUARY 3, 2014***
Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
E4112
Breast Cancer
OtherECOG-ACRIN
E4512
Lung Cancer
IIIECOG-ACRINA Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
E5508
Lung Cancer
IIIECOG-ACRINRandomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed or Both Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Stage Non-Squamous Non-Small Cell Lung Cancer
E7208
Gastrointestinal Cancer
IIECOG-ACRINA Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
LAO-MA036
Protocol IDPhaseLead OrganizationProtocol Title
9676
Multiple Cancers
ILAO-MA036
LAO-MN026
Protocol IDPhaseLead OrganizationProtocol Title
9608
Multiple Cancers
ILAO-MN026A Phase I Trial of ABT-263, a Bcl-2 inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors
LAO-TX035
Protocol IDPhaseLead OrganizationProtocol Title
9571
Multiple Cancers
ILAO-TX035A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer
MPC
Protocol IDPhaseLead OrganizationProtocol Title
8233
Multiple Cancers
IIMPCA Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer
NCICCR
Protocol IDPhaseLead OrganizationProtocol Title
9177
Lymphoma
IINCICCR***Effective February 26, 2014 enrollment to the MYC positive DLBCL arm of the study (including plasmablastic lymphoma) is halted as the accrual target has been met. The study remains open for patients with untreated Burkitt lymphoma.***
Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
NRG
Protocol IDPhaseLead OrganizationProtocol Title
GOG-0076HH
Gynecologic Cancer
I/IINRG
GOG-0213
Gynecologic Cancer
IIINRG
GOG-0229O
Gynecologic Cancer
IINRG
GOG-0238
Gynecologic Cancer
IINRGA Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus
GOG-0241
Gynecologic Cancer
IIINRG***ACCRUAL TO THIS TRIAL HAS BEEN SUSPENDED IMMEDIATELY EFFECTIVE OCTOBER 28, 2013***
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent Bevacizumab (NSC #704865, IND #7921) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian tube Cancer (MEOC)
GOG-0258
Gynecologic Cancer
IIINRGA Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
GOG-0263
Gynecologic Cancer
IIINRGRandomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
GOG-0275
Gynecologic Cancer
IIINRGA Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
GOG-0277
Gynecologic Cancer
IIINRGA Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) v. Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma
GOG-0286B
Gynecologic Cancer
II/IIINRG
GOG-9924
Gynecologic Cancer
INRG
GOG-9926
Gynecologic Cancer
INRG
GOG-9927
Gynecologic Cancer
INRG
NRG-BN001
Multiple Cancers
IINRG
NRG-BR002
Breast Cancer
II/IIINRG
NRG-CC002
Gynecologic Cancer
OtherNRG
NRG-GI001
Gastrointestinal Cancer
IIINRGRandomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
NRG-GU001
Genitourinary Cancer
IINRG
NRG-GY001
Gynecologic Cancer
IINRG
NRG-HN001
Head and Neck Cancer
II/IIINRGRandomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
NRG-HN002
Head and Neck Cancer
IINRG
NSABP-B-43
Breast Cancer
IIINRGA Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy
NSABP-B-47
Breast Cancer
IIINRGA Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
NSABP-B-51
Breast Cancer
IIINRGA Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
NSABP-B-52
Breast Cancer
IIINRGA Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
NSABP-B-55
Breast Cancer
IIINRGA Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
RTOG-0524
Genitourinary Cancer
I/IINRG***STEP 1 OF THIS STUDY CLOSED TO ACCRUAL EFFECTIVE FEBRUARY 22, 2013***
A Phase I/II Trial of a combination of Paclitaxel And Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer
RTOG-0534
Genitourinary Cancer
IIINRGA Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy
RTOG-0724
Gynecologic Cancer
IIINRG***STUDY TEMPORARILY CLOSED EFFECTIVE 02/28/2014 at 5:00pm EST***
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
RTOG-0815
Genitourinary Cancer
IIINRGA Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
RTOG-0834
Brain Cancer
IIINRGPHASE III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup Trial
RTOG-0839
Lung Cancer
IINRG
RTOG-0848
Gastrointestinal Cancer
IIINRGA Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
RTOG-0912
Head and Neck Cancer
IINRGA Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
RTOG-0920
Head and Neck Cancer
IIINRGA Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
RTOG-0924
Genitourinary Cancer
IIINRGAndrogen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
RTOG-0925
CNS Neoplasms (Primary Tumor)
IINRGNatural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients with Supratentorial Low-Risk Grade II Glioma
RTOG-0937
Lung Cancer
IINRGRandomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC)
RTOG-1008
Head and Neck Cancer
IINRGA Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
RTOG-1010
Gastrointestinal Cancer
IIINRGA Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment Of HER2-Overexpressing Esophageal Adenocarcinoma
RTOG-1016
Head and Neck Cancer
IIINRG***CLOSED to accrual EFFECTIVE 07/31/2014 at 5PM EDT***
***The quality of life (QOL) component has met its accrual objective (400 patients) and closed to accrual on 02/28/13. The trial remains open to accrual to the treatment and translational research components.***
Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
RTOG-1112
Gastrointestinal Cancer
IIINRGRandomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
RTOG-1115
Genitourinary Cancer
IIINRGPhase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer
RTOG-1201
Gastrointestinal Cancer
IINRG
RTOG-1203
Gynecologic Cancer
IIINRGA Randomized Phase III Study of Standard VS IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)
RTOG-1205
Brain Cancer
IINRG
RTOG-1216
Head and Neck Cancer
II/IIINRGRandomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Cetuximab and Docetaxel for High-Risk Squamous Cell Cancer of the Head and Neck
RTOG-1221
Head and Neck Cancer
IINRGRandomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery followed by Risk-Based IMRT and Weekly Cisplatin versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer
RTOG-1306
Lung Cancer
IINRGA Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
RTOG-1308
Lung Cancer
IIINRGPhase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
NY018
Protocol IDPhaseLead OrganizationProtocol Title
8854
Leukemia
IINY018Randomized Phase II Study of Epigenetic Priming Using Decitabine with Induction Chemotherapy in Patients with Acute Myelogenous Leukemia (AML)
OH029
Protocol IDPhaseLead OrganizationProtocol Title
9434
Gynecologic Cancer
IIOH029Randomized phase II study of intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine® NSC #663249) cisplatin-radiochemotherapy versus intravenous cisplatin-radiochemotherapy in women diagnosed with stage IB-IVA cervical cancer and stage II-IVA vaginal cancer
P2C-CA189
Protocol IDPhaseLead OrganizationProtocol Title
9653
Genitourinary Cancer
IIP2C-CA189
SCUSF
Protocol IDPhaseLead OrganizationProtocol Title
SCUSF-0806
Breast Cancer
IISCUSFPhase II placebo-controlled trial of lisinopril and Coreg CR to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin)
SWOG
Protocol IDPhaseLead OrganizationProtocol Title
S0711
Gastrointestinal Cancer
ISWOG
S0812
Breast Cancer
IISWOG***This study will be permanently closed to participants who do not plan to submit core needle biopsies. The study will remain open until further notice, to participants who do plan to submit core needle breast biopsies.***
Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of High Dose Vitamin D in Premenopausal Women at High Risk for Breast Cancer Phase IIB
S0819
Lung Cancer
IIISWOGA Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
S0820
Gastrointestinal Cancer
IIISWOGA Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
S0931
Genitourinary Cancer
IIISWOGEVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.
S1001
Lymphoma
IISWOGA Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
S1007
Breast Cancer
IIISWOGA Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
S1011
Genitourinary Cancer
IIISWOGA Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.
S1117
Leukemia
IISWOG***Study Temporarily Closed Effective 4/15/14 at 11:50 pm PST***
A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
S1201
Gastrointestinal Cancer
IISWOGA Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer
S1202
Breast Cancer
IIISWOGA Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
S1203
Leukemia
IIISWOGA Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) Versus IA with Vorinostat (NSC-701852) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
S1207
Breast Cancer
IIISWOGPhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy
S1211
Myeloma
I/IISWOGA Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
S1216
Genitourinary Cancer
IIISWOGA Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
S1304
Myeloma
IISWOGA Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
S1314
Genitourinary Cancer
IISWOG
S1316
Gastrointestinal Cancer
IIISWOG
S1318
Leukemia
IISWOG
S1320
Melanoma
IISWOG
S1400
Lung Cancer
II/IIISWOGPhase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
S1400A
Lung Cancer
II/IIISWOG
S1400B
Lung Cancer
II/IIISWOG
S1400C
Lung Cancer
II/IIISWOG
S1400D
Lung Cancer
II/IIISWOG
S1400E
Lung Cancer
II/IIISWOG
S1403
Lung Cancer
II/IIISWOG